Lete-cel
Cancer
Sold/TransferredTransferred to US WorldMeds; Adaptimmune supporting for future approval
Key Facts
Indication
Cancer
Phase
Sold/Transferred
Status
Transferred to US WorldMeds; Adaptimmune supporting for future approval
Company
About Adaptimmune Therapeutics
Adaptimmune is a UK-based biotech focused on developing novel TCR T-cell therapies for cancer. The company recently underwent significant strategic changes, including the sale of its TECELRA, lete-cel, afami-cel, and uza-cel programs to US WorldMeds, delisting from Nasdaq, and a leadership overhaul. Its current strategy centers on advancing its earlier-stage PRAME and CD70-targeting programs while reducing operational costs as a private entity.
View full company profileTherapeutic Areas
Other Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Shared Antigen mRNA Cancer Vaccines | BioNTech | Phase 2 |
| Targeted Oncology Therapies | BioNTech | Phase 1/2 |
| ARGX-119 | Argenx | Phase 1 |
| Oncology Program | Shionogi | Clinical |
| Bmab (Bevacizumab) | Biocon | Approved |
| Ciforadenant (CPI-444) | Corvus Pharmaceuticals | Phase 1/2 |
| Mupadolimab (CPI-006) | Corvus Pharmaceuticals | Phase 1 |
| tovecimig | Compass Therapeutics | Clinical |
| CTX-8371 | Compass Therapeutics | Clinical |
| XmAb 14045 | Xencor | Clinical |
| XmAb 13676 | Xencor | Clinical |
| Vibostolimab | Xencor | Clinical |